This article takes a look at how people's expectations of connectivity in their everyday lives should inform how we approach medical diagnostic devices, and how connected, data-gathering tests could transform diagnostics, using the current pandemic as an example.READ MORE
With life science industries facing increased competition, global regulatory demands, and pressure to shorten time to market, outsourcing part – or all – manufacturing is becoming increasingly prevalent. But what should be considered in choosing such a custom or contract manufacturing partner?READ MORE
In the final part of our exclusive interview series with Blue Brain Project Founder and Director Professor Henry Markram, we discuss the goals that he has strived towards over the last 15 years – simulating the mouse, and eventually human, brain. We discuss the Blue Brain Project’s achievements and setbacks and Markram explains what he feels are the Project’s most surprising findings. Finally, we look towards the future – when will we have simulated the human brain?
In the second of our exclusive three-part interview series with Blue Brain Project Founder and Director Professor Henry Markram, we discuss how brain simulations can benefit neuroscience.
The EPFL Blue Brain Project (BBP) is a Swiss National Research Infrastructure project which has spent the last 15 years trying to advance the cause of simulation neuroscience. Through successes and headwinds, the BBP has been led since inception by Professor Henry Markram. Read all three parts of our exclusive interview series with Markram now.READ MORE
Researchers are using sequencing technologies to rapidly expand our knowledge of the human microbiome and identify undiscovered bacterial genomes.READ MORE
In the first of our exclusive three-part interview series with Blue Brain Project Founder and Director Professor Henry Markram, we discuss the basics of simulation neuroscience. Markram, one of the leading proponents of the field, comments on why the idea of simulating the brain has raised concerns from experimental and theoretical neuroscientists and answers whether in silico techniques could ultimately replace experimental approaches.
In this article, we explore recent developments related to cell-based phenotypic screening, discuss the elements of a good phenotypic drug screen, and discover how these approaches are helping to provide a more accurate biological context for drug screening.READ MORE
The inescapable fact for modern businesses is that data is now the backbone of every organisation. In this article, IDBS's Abhay Kini discusses how cloud technology helping life science firms with data reproducibility, sharing, collation and storage across drug development.READ MORE